Amarin Corp Plcuk (AMRN) Cash from Investing Activities Growth (3y) (2015 - 2026)
Amarin Corp Plcuk (AMRN) Cash from Investing Activities Growth (3y) (2015 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-58.55% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
-78.48% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-32.26% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-4.78% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-62.97% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-36.21% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
60.61% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-38.13% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
14.56% |
| 10 |
Amarin Corp Plcuk |
5.84 Bn |
5.66 Bn |
17.77 Mn |
24.92% |
| Date | Value |
|---|
| Mar 31, 2026 |
24.92% |
| Dec 31, 2025 |
49.82% |
| Sep 30, 2025 |
-33.76% |
| Jun 30, 2025 |
-44.65% |
| Mar 31, 2025 |
-50.43% |
| Dec 31, 2024 |
-42.82% |
| Sep 30, 2024 |
17.16% |
| Jun 30, 2024 |
-54.74% |
| Mar 31, 2024 |
-39.22% |
| Dec 31, 2023 |
-70.97% |
| Sep 30, 2023 |
108.46% |
| Jun 30, 2023 |
32.67% |
| Mar 31, 2023 |
59.44% |
| Dec 31, 2022 |
-324.37% |
| Sep 30, 2022 |
194.37% |
| Dec 31, 2021 |
1,610.57% |
| Mar 31, 2020 |
-2,803.81% |
| Dec 31, 2018 |
34.75% |
| Mar 31, 2016 |
-14.47% |
| Dec 31, 2015 |
88.75% |
